Replimune REPL
NASDAQ REPL
$23.28 +1.02 (+4.58%)
At close: Nov 10, 2026 · 4:00 PM EST

Replimune (REPL) Net Margin (2017 - 2018)

Updated

Replimune's Net Margin came in at -869.95% for fiscal Q3 2019 (quarter ended Dec 31, 2018), up 12736.30 percentage points from -13606.25% a year earlier and up 103.09 percentage points from the prior quarter.

Analysis

Replimune (REPL) Net Margin (2017 - 2018) Analysis & Trends

Over the trailing twelve months to Dec 31, 2018, Replimune reported Net Margin of -1718.89%.

  • Year-over-year, Net Margin has increased for three consecutive quarters.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 26.44%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 0.83%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 24.24%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 28.01%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 22.65%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 16.30%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 37.28%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 29.27%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 19.55%
10 Replimune 2.40 Bn 1.35 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -869.95%
Sep 30, 2018 -973.04%
Jun 30, 2018 -4,424.67%
Dec 31, 2017 -13,606.25%
Sep 30, 2017 -46,600.00%
Jun 30, 2017 -11,840.00%
API Access

Replimune Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=REPL&period=max&api_key=YOUR_API_KEY